Skip to main content
SpringerLink
Log in

Treatment of Melanoma CNS Metastases

  • Chapter
  • First Online:
Melanoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 167))

Abstract

The discovery of the BRAFV600 mutation and the development of targeted therapies directed against this mutation as well as effective immunotherapies with durable benefits have revolutionized the treatment of patients with melanoma. Nonetheless, the frequent occurrence of brain metastases in patients with advanced melanoma represents a significant obstacle to long-term, high quality survival. The application of stereotactic radiation therapy has provided an opportunity to control brain metastases in the majority of patients with metastatic melanoma reducing the impact of these lesions on morbidity and mortality and enabling patients to receive and potentially benefit from these novel systemic treatments. Encouragingly, several of these novel new therapies have shown antitumor activity against CNS metastases that approach that seen against extracranial disease. As a consequence, several effective treatment options are now available for patients with melanoma brain metastases. With these tools in hand, it is anticipated that further investigation into the optimal sequence and/or combination of systemic therapies and local therapies along with multidisciplinary team practice will continue to improve the outcome of patients with this previously life-limiting disease complication.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Rankin EM (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22(11):2101–2107. doi:10.1200/jco.2004.11.044

    Article  CAS  PubMed  Google Scholar 

  2. Alessandretti M, Buzaid AC, Brandao R, Brandao EP (2013) Low-dose bevacizumab is effective in radiation-induced necrosis. Case Rep Oncol 6(3):598–601. doi:10.1159/000357401

    Article  PubMed Central  PubMed  Google Scholar 

  3. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665–1672. doi:10.1016/s0140-6736(04)16250-8

    Article  PubMed  Google Scholar 

  4. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Margolin KA (2008) Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113(8):2139–2145. doi:10.1002/cncr.23805

    Article  CAS  PubMed  Google Scholar 

  5. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Zagars GK (2006) Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 64(1):106–113. doi:10.1016/j.ijrobp.2005.06.030

    Article  PubMed  Google Scholar 

  6. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P (2011) Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 34(6):603–610. doi:10.1097/COC.0b013e3181f9456a

    Article  PubMed  Google Scholar 

  7. Bindal RK, Sawaya R, Leavens ME, Lee JJ (1993) Surgical treatment of multiple brain metastases. J Neurosurg 79(2):210–216. doi:10.3171/jns.1993.79.2.0210

    Article  CAS  PubMed  Google Scholar 

  8. Carlino MS, Atkins MB, Warneke CL et al (2010) Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: Analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study. Paper presented at the Melanoma Congress

    Google Scholar 

  9. Chang EL, Selek U, III Hassenbusch SJ, Maor MH, Allen PK, Mahajan A, Woo SY (2005). Outcome variation among “radioresistant” brain metastases treated with stereotactic radiosurgery. Neurosurgery 56(5):936–945 (discussion 936–945)

    Google Scholar 

  10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. doi:10.1056/NEJMoa1103782

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Chen G, Davies MA (2012) Emerging insights into the molecular biology of brain metastases. Biochem Pharmacol 83(3):305−314

    Google Scholar 

  12. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954. doi:10.1038/nature00766

    Article  CAS  PubMed  Google Scholar 

  13. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687–1696. doi:10.1002/cncr.25634

    Article  PubMed  Google Scholar 

  14. de la Monte SM, Moore GW, Hutchins GM (1983) Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 43(7):3427–3433

    PubMed  Google Scholar 

  15. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Rinderknecht JD (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50(3):611–621. doi:10.1016/j.ejca.2013.11.002

    Article  CAS  PubMed  Google Scholar 

  16. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Kefford RF (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893–1901. doi:10.1016/s0140-6736(12)60398-5

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Fertil B, Malaise EP (1985) Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11(9):1699–1707

    Article  CAS  PubMed  Google Scholar 

  18. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Thompson JF (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22(7):1293–1300. doi:10.1200/jco.2004.08.140

    Article  CAS  PubMed  Google Scholar 

  19. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703. doi:10.1056/NEJMoa1210093

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Schadendorf D (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114. doi:10.1056/NEJMoa1203421

    Article  CAS  PubMed  Google Scholar 

  21. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Kalkanis SN (2010) The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):17–32. doi:10.1007/s11060-009-0060-9

    Article  PubMed Central  PubMed  Google Scholar 

  22. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445(7130):851–857. doi:10.1038/nature05661

    Article  CAS  PubMed  Google Scholar 

  23. Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, Schwartzentruber DJ (2002) Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 25(1):82–87

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134–144. doi:10.1056/NEJMoa1305133

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Hauschild A, Grob JJ, Demidov LV et al (2013) An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)

    Google Scholar 

  26. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365. doi:10.1016/s0140-6736(12)60868-x

    Article  CAS  PubMed  Google Scholar 

  27. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Mihm M (2008) CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5(9):557–561. doi:10.1038/ncponc1183

    Article  CAS  PubMed  Google Scholar 

  29. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM (2010) Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 16(19):4892–4898. doi:10.1158/1078-0432.ccr-10-1507

    Article  CAS  PubMed  Google Scholar 

  30. Hurst R, White DE, Heiss J, Lee DS, Rosenberg SA, Schwartzentruber DJ (1999) Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? J Immunother 22(4):356–362

    Article  CAS  PubMed  Google Scholar 

  31. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Houghton AN (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103(12):2590–2597. doi:10.1002/cncr.21081

    Article  CAS  PubMed  Google Scholar 

  32. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF et al (1990) Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66(9):1873–1878

    Article  CAS  PubMed  Google Scholar 

  33. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Davies MA (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014–4023. doi:10.1002/cncr.26724

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Jensen CA, Chan MD, McCoy TP, Bourland JD, deGuzman AF, Ellis TL, Tatter SB (2011) Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg 114(6):1585–1591. doi:10.3171/2010.11.jns10939

    Article  PubMed Central  PubMed  Google Scholar 

  35. Johnson JD, Young B (1996) Demographics of brain metastasis. Neurosurg Clin N Am 7(3):337–344

    CAS  PubMed  Google Scholar 

  36. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Linskey ME (2010) The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):33–43. doi:10.1007/s11060-009-0061-8

    Article  PubMed Central  PubMed  Google Scholar 

  37. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117(2):227–233. doi:10.3171/2012.5.jns111929

    Article  PubMed  Google Scholar 

  38. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29(2):134–141. doi:10.1200/jco.2010.30.1655

    Article  PubMed Central  PubMed  Google Scholar 

  39. Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, Lunsford LD (2011) Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 114(3):769–779. doi:10.3171/2010.5.jns1014

    Article  PubMed  Google Scholar 

  40. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246. doi:10.1200/jco.2010.32.4327

    Article  PubMed  Google Scholar 

  41. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095. doi:10.1016/s1470-2045(12)70431-x

    Article  CAS  PubMed  Google Scholar 

  42. Lwu S, Goetz P, Monsalves E, Aryaee M, Ebinu J, Laperriere N, Zadeh G (2013) Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases. Oncol Rep 29(2):407–412. doi:10.3892/or.2012.2139

    CAS  PubMed Central  PubMed  Google Scholar 

  43. Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Johnson D (2002) Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128(4):214–218. doi:10.1007/s00432-002-0323-8

    Article  CAS  PubMed  Google Scholar 

  44. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465. doi:10.1016/s1470-2045(12)70090-6

    Article  CAS  PubMed  Google Scholar 

  45. Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, Atkins MB (1990) Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76(10):1933–1940

    CAS  PubMed  Google Scholar 

  46. Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, Enrici RM (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48. doi:10.1186/1748-717x-6-48

    Article  PubMed Central  PubMed  Google Scholar 

  47. Mitchell MS (1989) Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7(11):1701–1709

    CAS  PubMed  Google Scholar 

  48. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF (2013) Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 344(3):655–664. doi:10.1124/jpet.112.201475

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Clavel M (2003) A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13(1):97–103. doi:10.1097/01.cmr.0000043161.28051.2d

    Article  CAS  PubMed  Google Scholar 

  50. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, Pavlick AC (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113(3):411–416. doi:10.1007/s11060-013-1127-1

    Article  CAS  PubMed  Google Scholar 

  51. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17):1485–1489

    Article  CAS  PubMed  Google Scholar 

  52. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500. doi:10.1056/nejm199002223220802

    Article  CAS  PubMed  Google Scholar 

  53. Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135(6):807–810

    Article  CAS  PubMed  Google Scholar 

  54. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Wolchok JD (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925–931. doi:10.1056/NEJMoa1112824

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  55. Radbill AE1, Fiveash JF, Falkenberg ET, Guthrie BL, Young PE, Meleth S, Markert JM (2004) Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 101(4):825−833

    Google Scholar 

  56. Ramakrishna N, Margolin KA (2013) Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book 33:399–403. doi:10.1200/EdBook_AM.2013.33.399

    Article  Google Scholar 

  57. Robert C, Thomas L, Bondarenko I, O’Day S, Jeffrey Weber MD, Garbe C, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526. doi:10.1056/NEJMoa1104621

    Google Scholar 

  58. Rochet NM, Kottschade LA, Markovic SN (2011) Vemurafenib for melanoma metastases to the brain. N Engl J Med 365(25):2439–2441. doi:10.1056/NEJMc1111672

    Article  CAS  PubMed  Google Scholar 

  59. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550–4557. doi:10.1158/1078-0432.ccr-11-0116

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Samlowski WE, Watson GA, Wang M, Rao G, Klimo P Jr, Boucher K, Jensen RL (2007) Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 109(9):1855–1862. doi:10.1002/cncr.22605

    Article  PubMed  Google Scholar 

  61. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1):11–20. doi:10.3171/jns.1998.88.1.0011

    Article  CAS  PubMed  Google Scholar 

  62. Schartz NE, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A, Lebbe C (2010) Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 20(3):247–250. doi:10.1097/CMR.0b013e3283364a37

    PubMed  Google Scholar 

  63. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698–2705

    Article  PubMed  Google Scholar 

  64. Schulze B, Meissner M, Wolter M, Rodel C, Weiss C (2014) Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 190(2):229–232. doi:10.1007/s00066-013-0474-3

    Article  CAS  PubMed  Google Scholar 

  65. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, Bottomley A (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31(1):65–72. doi:10.1200/jco.2011.41.0639

    Article  PubMed  Google Scholar 

  66. Soltys SG, Adler JR, Lipani JD, Jackson PS, Choi CY, Puataweepong P, Chang SD (2008) Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 70(1):187–193. doi:10.1016/j.ijrobp.2007.06.068

    Article  PubMed  Google Scholar 

  67. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419–425. doi:10.1200/jco.2011.38.0527

    Article  PubMed Central  PubMed  Google Scholar 

  68. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Marais R (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366(3):207–215. doi:10.1056/NEJMoa1105358

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.1056/NEJMoa1200690

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  70. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33(6):583–590. doi:10.1002/ana.410330605

    Article  CAS  PubMed  Google Scholar 

  71. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855–867

    Article  CAS  PubMed  Google Scholar 

  72. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133. doi:10.1056/NEJMoa1302369

    Article  CAS  PubMed  Google Scholar 

  73. Yu C, Chen JC, Apuzzo ML, O’Day S, Giannotta SL, Weber JS, Petrovich Z (2002) Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 52(5):1277–1287

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

    Sekwon Jang & Michael B. Atkins

Authors
  1. Sekwon Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael B. Atkins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael B. Atkins .

Editor information

Editors and Affiliations

  1. Rutgers Cancer Institute of New Jersey, New Brunswick, New York, USA

    Howard L. Kaufman

  2. Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA

    Janice M. Mehnert

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Jang, S., Atkins, M.B. (2016). Treatment of Melanoma CNS Metastases. In: Kaufman, H., Mehnert, J. (eds) Melanoma. Cancer Treatment and Research, vol 167. Springer, Cham. https://doi.org/10.1007/978-3-319-22539-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22539-5_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22538-8

  • Online ISBN: 978-3-319-22539-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation